Elanco Animal Health

ELAN

Market cap $11.9B

Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript

Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmab Starts controlling itch within 24 hours and is given as an in-clinic injection Select Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomes Meet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their journeys to itch relief Befrena is Elanco's second monoclonal antibody to launch in the U.S. pet health market, joining Trutect™, the first and only approved therapeutic solution to treat canine parvovirus and has been shown to be effective for passive immunity INDIANAPOLIS, May 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the phased launch of Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody (mAb) injection for treatment of canine allergic and atopic dermatitis. The launch comes at a key time, with a longer and more intense allergy season anticipated across the country this year.i With nearly 2 in 3 itchy dogs experiencing worse itch during allergy seasonii, Befrena expands Elanco's dermatology portfolio by offering a new treatment option that starts controlling allergic itch within 24 hours.

INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, May 27, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the Stifel 2026 Jaws & Paws Conference at 8:00 a.m.

Elanco Animal Health NYSE: ELAN raised its 2026 outlook after reporting stronger-than-expected first-quarter results, citing broad-based growth across pet health and farm animal businesses, accelerating demand for new products and continued debt reduction.

Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript

Elanco Animal Health CEO Jeff Simmons discusses response to screwworm outbreak concerns on 'The Claman Countdown.'

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) are trading higher on Wednesday, following a recent announcement regarding the approval of its products, Negasunt Powder and Tanidil, which received emergency use authorization.

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.37 per share a year ago.

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target First Quarter 2026 Financial Results: Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growth Reported Net Income of $57 million, Adjusted Net Income of $204 million Adjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5% Reported EPS of $0.11, Adjusted EPS of $0.40 Net leverage ratio of 3.5x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.2 billion Raising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growth Raising Adjusted EBITDA to $975 million to $1,005 million, a year-over-year increase of 10% at midpoint Raising Adjusted EPS of $1.03 to $1.09, a year-over-year increase of 13% at midpoint Improving year-end net leverage ratio target to 3.0x to 3.2x Adjusted EBITDA INDIANAPOLIS, May 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2026, provided guidance for the second quarter of 2026, and updated guidance for the full year 2026. "Elanco's strong first quarter results demonstrate the significant momentum of our innovation-led strategy," said Jeff Simmons, President and CEO of Elanco.

Elanco Animal Health (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.